Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.51 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.51 |
| ▸ | TST | Q16762 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 2/20 | 0.45 |
| ▸ | MANBA | O00462 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascorbic Acid SCHEMBL31676316 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL2564750 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL10957988 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL18678 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL786 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL785 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL734589 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL11981759 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL21114349 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL30704238 | 1.00 | MAPT (1.00) | MAPTLMNAL3MBTL1HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3199536-B1 | PREPARATION METHOD FOR BENZOXAZOLEOXAZINE KETONE COMPOUND AND INTERMEDIATE AND CRYSTAL FORM THEREOF | NORTH CHINA PHARMACEUTICAL NEW DRUG R&D CO LTD (DE) | 2020-06-10 | — | — | EP | disclosed |
| EP-3646770-A1 | ENDOSCOPE FLEXIBLE TUBE, ENDOSCOPE-TYPE MEDICAL DEVICE, RESIN COMPOSITION FOR COATING ENDOSCOPE FLEXIBLE-TUBE SUBSTRATE, AND RESIN COMPOSITION SET FOR COATING ENDOSCOPE FLEXIBLE-TUBE SUBSTRATE | FUJIFILM Corporation (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-20170275299-A1 | PREPARATION METHOD FOR BENZOXAZOLEOXAZINE KETONE COMPOUND AND INTERMEDIATE AND CRYSTAL FORM THEREOF | NORTH CHINA PHARMACEUTICAL NEW DRUG R&D CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-20170275299-A1 | PREPARATION METHOD FOR BENZOXAZOLEOXAZINE KETONE COMPOUND AND INTERMEDIATE AND CRYSTAL FORM THEREOF | NORTH CHINA PHARMACEUTICAL NEW DRUG R&D CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| EP-3199536-A1 | PREPARATION METHOD FOR BENZOXAZOLEOXAZINE KETONE COMPOUND AND INTERMEDIATE AND CRYSTAL FORM THEREOF | North China Pharmaceutical New Drug R&D Co., Ltd. (DE) | 2017-08-02 | — | — | EP | disclosed |
| EP-1592837-B1 | NON-YELLOWING ALDEHYDE CONDENSATION PRODUCTS | CLARIANT FINANCE BVI LTD (VG) | 2013-04-03 | — | — | EP | disclosed |
| US-20060134446-A1 | Non-yellowing aldehyde condensation products | CLARIANT FINANCE (BVI) LIMITED (VG) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275299-A1 | PREPARATION METHOD FOR BENZOXAZOLEOXAZINE KETONE COMPOUND AND INTERMEDIATE AND CRYSTAL FORM THEREOF | CYP4F11, CYP51A1, CYP2F1 | MAPT 1877/4885LMNA 1235/4885L3MBTL1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.